{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:58:39Z","timestamp":1733875119804,"version":"3.30.1"},"reference-count":17,"publisher":"CAIRN","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,3]]},"abstract":"<jats:p>Introduction\u00a0: L\u2019implication des pharmaciens d\u2019officine dans le\u00a0d\u00e9pistage des maladies cardio-neurovasculaires (MCNV) permettrait de renforcer la pr\u00e9vention du risque cardio-neurovasculaire. Une recherche-action a \u00e9t\u00e9 men\u00e9e afin d\u2019\u00e9valuer la pertinence d\u2019un mod\u00e8le combinant rep\u00e9rage et d\u00e9pistage cibl\u00e9 des facteurs de risque cardio-neurovasculaire en pharmacies d\u2019officine. Mat\u00e9riel et m\u00e9thodes\u00a0: Cette \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e sur le secteur de Lens-H\u00e9nin\u00a0(62) sur une p\u00e9riode de quatre mois. Le mod\u00e8le comprenait\u00a0: un rep\u00e9rage des patients \u00e0 risque selon leurs \u00e2ge, sexe, poids, ant\u00e9c\u00e9dents tabagiques, ant\u00e9c\u00e9dents cardiovasculaires familiaux, \u00e0 l\u2019exclusion des patients connus pour une\u00a0MCNV\u00a0; un d\u00e9pistage des facteurs de risque cardio-neurovasculaire avec mesure de la tension art\u00e9rielle, de la cholest\u00e9rol\u00e9mie totale, du cholest\u00e9rol HDL et de la glyc\u00e9mie via un pr\u00e9l\u00e8vement capillaire ainsi qu\u2019une mesure du p\u00e9rim\u00e8tre abdominal et de l\u2019IMC. Les patients ont \u00e9t\u00e9 orient\u00e9s vers le m\u00e9decin g\u00e9n\u00e9raliste en fonction des r\u00e9sultats du d\u00e9pistage. R\u00e9sultats\u00a0: Parmi les 471\u00a0patients d\u00e9pist\u00e9s, 218 (46\u00a0%) pr\u00e9sentaient au moins deux facteurs de risque, 236 (50\u00a0%) avaient une cholest\u00e9rol\u00e9mie totale sup\u00e9rieure ou \u00e9gale \u00e0 2\u00a0g\/L, 176 (37,4\u00a0%) pr\u00e9sentaient une pression art\u00e9rielle sup\u00e9rieure \u00e0 la valeur seuil, 104 (22\u00a0%) avaient un IMC sup\u00e9rieur ou \u00e9gal \u00e0 30\u00a0kg\/m 2 , 217\u00a0(46\u00a0%), un p\u00e9rim\u00e8tre abdominal sup\u00e9rieur aux valeurs seuil et, chez 17 (5,3\u00a0%), une glyc\u00e9mie \u00e0 jeun anormale \u00e9tait d\u00e9pist\u00e9e. Une orientation vers le m\u00e9decin g\u00e9n\u00e9raliste a \u00e9t\u00e9 propos\u00e9e \u00e0 373\u00a0(79\u00a0%) patients et au moins 68 (18\u00a0%) ont consult\u00e9. Conclusion\u00a0: Cette exp\u00e9rimentation de rep\u00e9rage-d\u00e9pistage du risque cardio-neurovasculaire au sein des pharmacies d\u2019officine s\u2019av\u00e8re pertinente. Sa reproduction dans d\u2019autres territoires est \u00e0 l\u2019\u00e9tude.<\/jats:p>","DOI":"10.3917\/spub.187.0777","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T09:53:40Z","timestamp":1555581220000},"page":"777-783","source":"Crossref","is-referenced-by-count":0,"title":["Rep\u00e9rage-d\u00e9pistage cibl\u00e9 du risque cardio-neurovasculaire en\u00a0officine"],"prefix":"10.3917","volume":"Vol. 30","author":[{"given":"Pierrine","family":"Aly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Tempremant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Houppermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Maes-Patinier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Vanbockstael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Lemdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2273","reference":[{"key":"rb1","unstructured":"1Institut de veille sanitaire (InVS). Maladies cardio-neurovasculaires [Page internet]. [Visit\u00e9 le 17\/10\/2017]. En ligne\u00a0: http:\/\/invs.santepubliquefrance.fr\/Dossiers-thematiques\/Maladies-chroniques-et-traumatismes\/Maladies-cardio-neuro-vasculaires\/Introduction."},{"key":"rb2","unstructured":"2Gabet\u00a0A, Lamarche-Vadel\u00a0A, Chin\u00a0F, Oli\u00e9\u00a0V. Disparit\u00e9s r\u00e9gionales de la mortalit\u00e9 pr\u00e9matur\u00e9e par maladie cardiovasculaire en France (2008-2010) et \u00e9volutions depuis 2000-2002. Bull Epid\u00e9miol Hebd. 2014;(26):430-8. [Visit\u00e9 le 11\/01\/2018]. En ligne\u00a0: http:\/\/invs.santepubliquefrance.fr\/\/beh\/2014\/26\/2014_26_1.html."},{"key":"rb3","unstructured":"3Agence r\u00e9gionale de sant\u00e9 (ARS) Hauts de France, Observatoire r\u00e9gional de sant\u00e9 (ORS). Diagnostic territorialis\u00e9 des Hauts de France\u00a0: territoires de proximit\u00e9. Janvier\u00a02017. 86\u00a0p. [Visit\u00e9 le 2\/12\/2018]. En ligne\u00a0: http:\/\/or2s.fr\/images\/PRS\/2017_DiagnosticTerritorialiseDesHautsDeFrance_PRS2_HautsDeFrance.pdf."},{"key":"rb4","doi-asserted-by":"crossref","unstructured":"4Gabet\u00a0A, Chin\u00a0F, Lamarche-Vadel\u00a0A, Oli\u00e9\u00a0V. Disparit\u00e9s r\u00e9gionales de la mortalit\u00e9 pr\u00e9matur\u00e9e par maladies cardiovasculaires et \u00e9volutions temporelles, France. Rev Epidemiol Sant\u00e9 Publique. 2014;62(S5):S186.","DOI":"10.1016\/j.respe.2014.06.049"},{"key":"rb5","doi-asserted-by":"crossref","unstructured":"5Jusot\u00a0F. Les in\u00e9galit\u00e9s de recours aux soins\u00a0: bilan et \u00e9volution. Rev Epidemiol Sant\u00e9 Publique. 2013;61(3):163-9.","DOI":"10.1016\/j.respe.2013.05.011"},{"key":"rb6","unstructured":"6R\u00e9publique fran\u00e7aise. Loi n\u00b0\u00a02009-879 du 21\u00a0juillet 2009 portant r\u00e9forme de l\u2019h\u00f4pital et relative aux patients, \u00e0 la sant\u00e9 et aux territoires. Article\u00a038. JORF n\u00b0\u00a00167 du 22\u00a0juillet 2009. p.\u00a012184."},{"key":"rb7","doi-asserted-by":"crossref","unstructured":"7Willis\u00a0A, Rivers\u00a0P, Gray\u00a0LJ, Davies\u00a0M, Khunti\u00a0K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS ONE. 2014;9(4):e91157.","DOI":"10.1371\/journal.pone.0091157"},{"key":"rb8","doi-asserted-by":"crossref","unstructured":"8Kehrer\u00a0JP, James\u00a0DE. The role of pharmacists and pharmacy education in point-of-care testing. Am J Pharm Educ. 2016;80(8):129.","DOI":"10.5688\/ajpe808129"},{"key":"rb9","doi-asserted-by":"crossref","unstructured":"9Eades\u00a0CE, Ferguson\u00a0JS, O\u2019Carroll\u00a0RE. Public health in community pharmacy: A systematic review of pharmacist and consumer views. BMC Public Health. 2011;11:582.","DOI":"10.1186\/1471-2458-11-582"},{"key":"rb10","doi-asserted-by":"crossref","unstructured":"10Haugb\u00f8lle\u00a0LS, Herborg\u00a0H. Adherence to treatment: practice, education and research in Danish community pharmacy. Pharm Pract. 2009;7(4):185-94.","DOI":"10.4321\/S1886-36552009000400001"},{"key":"rb11","unstructured":"11ARS Bourgogne, ORS Bourgogne. \u00c9tude exploratoire du d\u00e9pistage du diab\u00e8te en officine. Exp\u00e9rimentation d\u2019une campagne en Sa\u00f4ne-et-Loire. Dijon\u00a0: ORS Bourgogne\u00a0; 2015. 42\u00a0p. [Visit\u00e9 le 22\/08\/2017]. En ligne\u00a0: http:\/\/www.orsbfc.org\/publication\/etude-exploratoire-du-depistage-du-diabete-en-officine-experimentation-dune-campagne-en-saone-et-loire\/."},{"key":"rb12","unstructured":"12Barbier\u00a0R. La Recherche-action existentielle [Page internet]. [Visit\u00e9 le 21\/08\/2017]. En ligne\u00a0: http:\/\/www.barbier-rd.nom.fr\/RAInternet.Html."},{"key":"rb13","doi-asserted-by":"crossref","unstructured":"13O\u2019Donovan\u00a0DO, Byrne\u00a0S, Sahm\u00a0LJ. Pharmacist\u2019s Use of screening tools to estimate risk of CVD: A Review of the literature. Pharmacy. 2014;2(1):27-39.","DOI":"10.3390\/pharmacy2010027"},{"key":"rb14","unstructured":"14Fourcade\u00a0N, Von Lennep\u00a0F, Gr\u00e9my\u00a0I, Bourdillon\u00a0F (dir.). L\u2019\u00e9tat de sant\u00e9 de la population en France\u00a0: Rapport\u00a02017. Paris, Saint-Maurice\u00a0: Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques (Drees), Sant\u00e9 publique France\u00a0; 2017. 436\u00a0p. [Visit\u00e9 le 11\/01\/2018]. En ligne\u00a0: http:\/\/drees.solidarites-sante.gouv.fr\/IMG\/pdf\/esp2017.pdf."},{"key":"rb15","unstructured":"15Institut Pasteur (Lille), Universit\u00e9 Louis-Pasteur Strasbourg\u00a01, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (Inserm). Enqu\u00eate MONA LISA\u00a0: Pr\u00e9sentation des premiers r\u00e9sultats. Strasbourg\u00a0: Universit\u00e9 Louis-Pasteur\u00a0; 2008. 10\u00a0p. [Visit\u00e9 le 11\/01\/2018]. En\u00a0ligne\u00a0: http:\/\/www.bdsp.ehesp.fr\/Base\/379922\/."},{"key":"rb16","doi-asserted-by":"crossref","unstructured":"16The\u00a0R, Chen\u00a0T, Krass\u00a0I. Consumer perspectives of pharmacist-delivered healtn information and screening services. Int\u00a0J\u00a0Pharm Pract. 2001;9(4):261-7.","DOI":"10.1111\/j.2042-7174.2001.tb01057.x"},{"key":"rb17","unstructured":"17Haute Autorit\u00e9 de sant\u00e9 (HAS). Pr\u00e9vention du risque cardiovasculaire & dyslipid\u00e9mies. Saint-Denis La\u00a0Plaine\u00a0: HAS\u00a0; 2017."}],"container-title":["Sant\u00e9 Publique"],"original-title":[],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:03Z","timestamp":1701993603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cairn.info\/revue-sante-publique-2018-6-page-777.htm?ref=doi"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4,3]]}},"URL":"https:\/\/doi.org\/10.3917\/spub.187.0777","relation":{},"ISSN":["0995-3914"],"issn-type":[{"type":"print","value":"0995-3914"}],"subject":[],"published":{"date-parts":[[2019,4,3]]}}}